XCancer

Pilot Imaging Study of Leukemia

Description:

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Sponsor:

University of Alabama at Birmingham

Phase:

Phase 1

Contacts:

Heme Onc Lead Nurse (CONTACT)

scc-iit-office@ouhsc.edu

1-405-271-8777

Jennifer Holter, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03633955 - Click here to see study on

ClinicalTrials.gov

FLT

Isotope(s):
Target(s):
  • cytosolic thymidine kinase 1
Ligand Class: Small Molecules
Inclusion
  • Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma
Exclusion

Exclusion Criteria Not Yet Provided